Incyte Completes Acquisition of Star Therapeutics’ Wholly Owned Vega Subsidiary, Expands Hematology Assets
INCY•Incyte completed the acquisition of Vega Therapeutics, making it a wholly owned subsidiary of Star Therapeutics and strengthening its hematology division. The deal adds advanced hematologic research assets to Incyte’s pipeline, positioning the company for expanded blood cancer treatment revenue.
1. Acquisition Completion
Incyte has officially completed its acquisition of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics. Vega’s research team and facilities will be integrated into Incyte’s hematology business unit under the existing corporate structure.
2. Hematology Portfolio Expansion
Vega’s pipeline comprises preclinical epigenetic and immuno-oncology programs targeting blood cancers. Adding these assets enhances Incyte’s development-stage portfolio, aiming to accelerate clinical milestones and support long-term revenue growth in hematology.
